Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 12;13:13. doi: 10.3389/fnint.2019.00013

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2019 Minalyan, Gabrielyan, Pietra, Taché and Wang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Repeated treatments with ghrelin agonist, HM01 did not modify motor impairments in 6-OHDA rat Parkinson’s disease (PD) model. Rats were microinjected with 6-OHDA or vehicle unilaterally into the medial forebrain bundle. HM01 (3 mg/kg) or vehicle was administered og daily for 12 days starting from 4 weeks after microinjection. Stepping (A) and apomorphine-induced rotation (B) tests were performed on the last 2 days at 4–6 h after HM01 treatment in vehicle and 6-OHDA rats. Data are mean ± standard error of the mean (SEM) and animal numbers per group indicated in the graphs. *p < 0.05 vs. vehicle/vehicle by one-way analysis of variance (ANOVA).